Effects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple Sclerosis

Inclusion Criteria: * Ability to give written informed consent to the study * Age range 18-65 years * Diagnosis of primary of secondary progressive MS according to 2017 revised Macdonald's criteria (Thompson et al., 2017), presenting with signs of symptoms of progressive dysfunction of the corticospinal tract * EDSS ≤ 6,5 * Ability to participate to the study protocol * No or stable (at least six months) DMT or rehabilitative treatments before study entry, and willingness not to change these therapies (including cannabinoids, SSRI, baclofen) during the study. Exclusion Criteria: * Relapsing-remitting MS or progressive MS presenting with signs of symptoms other than those typical of the ascending myelopathy phenotype (i.e. progressive cerebellar or cognitive involvement) * Female with positive pregnancy test at baseline or having active pregnancy plans * Comorbidities for which synaptic plasticity may be altered (i.e., Parkinson's disease, Alzheimer's disease, stroke) * Contraindications to TMS * History or presence of any unstable medical condition such as malignancy or infection * Use of medications with increased risk of seizures (i.e. Fampridine, 4-Aminopyridine) * Concomitant use of drugs that may alter synaptic transmission and plasticity (L-dopa, antiepileptics)